Although aminoglycosides are predominantly used for the treatment of gram-negative infections, they are also known to have antistaphylococcal activity (15) . This becomes an important consideration when patients are treated empirically for suspected sepsis with an aminoglycoside and ureidopenicillin, other penicillins, or cephalosporins susceptible to staphylococcal beta-lactamases. This type of empiric treatment is commonly administered to premature neonates, to patients with neutropenia, and occasionally to patients with suspected nosocomial infections (17, 21) due to enhanced clinical activity of such antimicrobial agent combinations in gram-negative sepsis (2) . In addition, the emergence of methicillin-resistant Staphylococcus aureus (22) and the widespread use of central lines associated with bacteremia due to Staphylococcus epidermidis (7) are increasing the clinical importance of the antistaphylococcal activity of aminoglycosides. Little is known about the emergence of amikacin resistance in staphylococci; nearly all epidemiological surveys have focused on the emergence of resistance in gram-negative bacteria (6, 10, 16, 18, 24) .
Resistance to tobramycin and gentamicin was observed both in coagulase-negative staphylococci and S. aureus in the intensive care units (ICUs) and burn unit at two McMaster University teaching hospitals during a period of exclusive tobramycin and gentamicin use. At that time, no resistance to amikacin was apparent. In view of the lack of clinically significant resistance developing in gram-negative bacteria when amikacin is introduced as the aminoglycoside of choice (6, 10, 16, 18, 24) , this prospective study was undertaken to determine the prevalence of resistance of coagulase-negative staphylococci and S. aureus to gentamicin, tobramycin, and amikacin before and after the introduction of amikacin as the only prescribed aminoglycoside in those units. * Corresponding author.
MATERIALS AND METHODS
Prevalence studies. Three different geographical areas were surveyed during four periods: the neonatal ICU, adult ICU, and burn unit. The ICUs were located at one hospital and the burn unit at another. The neonatal ICU is a 35-bed unit caring almost exclusively for premature babies. Gentamicin was used extensively in that unit. The adult ICU has a 15-bed capacity, and the burn unit has 6 beds. In both units, tobramycin was used. Surveillance studies were conducted in all three units for 4 considered to be S. aureus. Coagulase-negative isolates were not further identified and are therefore referred to as coagulase-negative staphylococci. Antimicrobial agent susceptibilities were determined by agar dilution. The method is similar to that described in the National Committee for Clinical Laboratory Standards performance standard M7-A but used Sensitest agar (Oxoid) in place of modified MuellerHinton agar. The antimicrobial-agent-containing medium was quality controlled daily with Escherichia coli ATCC 25922, S. aureus ATCC 29213, and Pseudomonas aeruginosa ATCC 27853. At least once per week, each batch of antimicrobial-agent-containing media was tested with an expanded range of 15 strains of control organisms having known and discriminatory MICs. The breakpoint for gentamicin and tobramycin was 4 ,ug/ml, for amikacin the breakpoint was 16 ,ug/ml, and it was 2 ,ug/ml for oxacillin. Detection of gentamicin-resistant subpopulations was determined by subculturing isolated colonies onto brain heart infusion agar (Oxoid) containing 5 ,ug of gentamicin per ml (23) . RESULTS A total of 2,613 strains of coagulase-negative staphylococci and 316 strains of S. aureus were obtained from 916 patients during the four surveillance periods. The numbers of patients colonized and the numbers of isolates obtained during each surveillance period are summarized in Table 1 .
During the course of the study, the percentage of patients colonized with amikacin-resistant coagulase-negative staphylococci increased from 0% before to 43% 30 to 31 months after amikacin was introduced ( A total of 384 coagulase-negative staphylococci strains were also oxacillin resistant. Most of these were also multiaminoglycoside resistant (Table 4) . DISCUSSION This is a survey of aminoglycoside resistance in S. aureus and coagulase-negative staphylococci before and after the introduction of amikacin. The vast majority of isolates merely colonized patients. The prevalence of infecting strains was so low that comparative analysis of colonizing versus invasive strains was not deemed worthwhile. Invasive strains of coagulase-negative staphylococci are usually multiply resistant (7, 14) . This most likely reflects the previous exposure of the patient to antimicrobial agents or admission to units where antimicrobial agents are widely used. Therefore, the practical concern is not that multiply resistant coagulase-negative staphylococci become more virulent but that they may be more difficult to treat and that they harbor resistance plasmids which may be transferred to other bacteria on skin and mucosal surfaces (13) .
Widespread aminoglycoside resistance developing in coagulase-negative staphylococci was previously reported. Weinstein resistant coagulase-negative staphylococci in a cardiac surgery unit increased from 20 to 68% over a period of 4 years (4). Based on our findings, it appears that amikacin resistance also develops quickly in coagulase-negative staphylococci after this aminoglycoside is introduced, but without a concomitant decrease in gentamicin and tobramycin resistance. In contrast, amikacin resistance does not appear to increase appreciably in gram-negative bacteria when this aminoglycoside is widely used (6, 10, 16, 24) . Furthermore, hospitals which switched from gentamicin or tobramycin to amikacin experienced a decrease over time in the resistance of gramnegative bacilli to gentamicin and tobramycin (6, 10, 16, 24) .
The amikacin resistance which we observed in coagulasenegative staphylococci was clearly associated with resistance to the other two aminoglycosides. A total of 99% of amikacin-resistant strains were also resistant to tobramycin and gentamicin. Whereas 83% of aminoglycoside-resistant strains were both gentamicin and tobramycin resistant before amikacin was introduced, this decreased to 40% in the last survey, in which 48% were resistant to all three aminoglycosides. This probably represents the emergence of genetically linked multiaminoglycoside resistance. Oxacillin resistance was also associated with aminoglycoside resistance, as was previously reported for methicillin (3, 19) . Linkage of multiple resistance on a single plasmid may account for the continuing high prevalence of tobramycin and gentamicin resistance even after the use of these antimicrobial agents was discontinued. This is currently being investigated by aminoglycoside-modifying enzyme analysis, plasmid isolation, and restriction endonuclease typing. In this study, isolates have not been tested for susceptibility to other aminoglycosides.
It is of interest that amikacin resistance did not develop in S. aureus. A much lower prevalence of gentamicin-resistant S. aureus than of coagulase-negative staphylococci was observed previously (1, 23) . There are a number of possibilities which may account for this. The number of patients colonized and the total number of bacteria are much higher for coagulase-negative staphylococci than for S. aureus. Hence, by probability, it is more likely for resistance to be observed in coagulase-negative staphylococci if resistance plasmids are equally likely to be acquired by different species of staphylococci. However, resistance plasmids may also be more easily acquired and maintained by coagulasenegative staphylococci than by S. aureus. This concept is supported by two observations. First, gentamicin resistance plasmids are more easily lost in vitro from S. aureus than from S. epidermidis (H. Bialkowska-Hobrzanska, personal communication), and second, a larger number of resistance plasmids are present in clinical isolates of S. epidermidis than in isolates of S. aureus (20) .
The appearance of similar resistance plasmids have been observed in both coagulase-negative staphylococci and S. (11, 12) , it is tempting to speculate that resistance may already have been transferred to some strains of S. aureus but is not being phenotypically expressed. This is yet another possibility to account for the absence of resistance in S. aureus. We believe this deserves further study.
